Table 2 Summary of recent studies... | American Society of Hematology

Table 2

Summary of recent studies (2003-present) assessing outcomes of therapeutic plasma exchange in TA-TMA

Author, year of publication	Patients receiving TPE/total patients with TA-TMA (n/n)	Response to TPE, %	Mortality, %	Additional findings and author conclusions
Hahn et al, 2004⁷³	19/19		84
Uderzo et al, 2006¹⁹	17/64	59	50 for all	Outcome influenced by defibrotide
Erdbruegger et al, 2006⁴³	5/5	40	20
Worel et al, 2007¹⁶	11/11	64		Treated prospectively with withdrawal of cyclosporine and TPE at TA-TMA diagnosis
Oran et al, 2007⁷²	63/66	64	100 for nonresponders 50 for responders	Response was related to GVHD and infection control
Cho et al, 2008³⁸	16/43		62 for all	TA-TMA should be treated early before it develops into definite tissue injury
P-TMA	5/27	80	48
D-TMA	11/16	27	92
Willems et al, 2010¹⁷	25/42	55 for all	80 for all	Median survival in responders 218 days versus 27 days in nonresponders

Author, year of publication	Patients receiving TPE/total patients with TA-TMA (n/n)	Response to TPE, %	Mortality, %	Additional findings and author conclusions
Hahn et al, 2004⁷³	19/19		84
Uderzo et al, 2006¹⁹	17/64	59	50 for all	Outcome influenced by defibrotide
Erdbruegger et al, 2006⁴³	5/5	40	20
Worel et al, 2007¹⁶	11/11	64		Treated prospectively with withdrawal of cyclosporine and TPE at TA-TMA diagnosis
Oran et al, 2007⁷²	63/66	64	100 for nonresponders 50 for responders	Response was related to GVHD and infection control
Cho et al, 2008³⁸	16/43		62 for all	TA-TMA should be treated early before it develops into definite tissue injury
P-TMA	5/27	80	48
D-TMA	11/16	27	92
Willems et al, 2010¹⁷	25/42	55 for all	80 for all	Median survival in responders 218 days versus 27 days in nonresponders

P-TMA indicates probable TA-TMA (see Table 1); and D-TMA, definite TA-TMA.